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Summary
Background: The expanding role of cardiac markers — cytosolic [heart-type fatty acid-binding
protein (H-FABP) and creatine kinase MB (CK-MB)], myoﬁbril [troponin T (TnT)], and cardio-
endocrine [N-terminal pro-B-type natriuretic peptide (NT-proBNP)] — has been clariﬁed in
patients with acute coronary syndrome and those with heart failure. However, these applica-
tions for early risk stratiﬁcation in the cardiac emergency, and the inﬂuence of renal function
on these evaluations have not been fully investigated.
Patients and methods: We investigated the prognostic value of these representative cardiac
markers and inﬂuence of renal function on these evaluations in 165 consecutive patients who
were admitted for cardiac emergency because of chest pain or dyspnea.
Results: There were signiﬁcant correlations between TnT and CK-MB (r = 0.512, p < 0.001), and
between H-FABP and TnT (r = 0.409, p < 0.001) and CK-MB (r = 0.254, p < 0.01); however, NT-
proBNP levels did not show signiﬁcant correlations with other cardiac markers. There were
signiﬁcant correlations between estimated glomerular ﬁltration rate and NT-proBNP (r =−0.466,
p < 0.001) and H-FABP (r =−0.235, p < 0.001) levels, and between left ventricular ejection
fraction (LVEF) and NT-proBNP (r =−0.407, p < 0.001) and H-FABP (r =−0.253, p < 0.01) levels.
∗ Corresponding author. Tel.: +81 0476 99 1111; fax: +81 0476 99 1873.
E-mail address: y-seino@nms.ac.jp (Y. Seino).
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Kaplan—Meier analysis showed that median of NT-proBNP, H-FABP, and CK-MB signiﬁcantly dis-
criminated in-hospital cardiovascular death, and multivariate analysis revealed NT-proBNP and
LVEF as independent prognostic predictors.
Conclusion: NT-proBNP is a novel biomarker for integrated cardio-renal burden, and extremely
useful for early risk stratiﬁcation in the situation of cardiac emergency.
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ing to the Framingham criteria, physical ﬁndings, and chest
X-ray ﬁndings.© 2010 Japanese College of C
ntroduction
he expanding role of cardiac markers, such as cytosolic
heart-type fatty acid-binding protein (H-FABP) and creatine
inase MB (CK-MB)], myoﬁbril [troponin T (TnT)], and cardio-
ndocrine [B-type natriuretic peptide (BNP) and N-terminal
ro-BNP (NT-proBNP)], has been clariﬁed in patients with
cute coronary syndrome, heart failure, and other cardio-
ascular diseases [1—6]. We have reported that NT-proBNP
s elevated in heart failure, and is a more discerning marker
f heart failure compared with BNP [7]. Large-scale clin-
cal trials have demonstrated that NT-proBNP is increased
n the early stage of acute coronary syndrome and is a
owerful predictor of short- and long-term mortality [8].
e have recently reported that NT-proBNP levels are ele-
ated signiﬁcantly higher in patients with non-ST-elevation
cute coronary syndrome than those with ST-elevation espe-
ially in the early phase of onset [9]. Renal function is
nother independent prognostic predictor in patients with
arious cardiovascular diseases [10—12]. Thus, the present
tudy investigated the prognostic value of the novel car-
iac markers CK-MB and H-FABP as cytosolic markers, TnT
s a myoﬁbril marker, and NT-proBNP as a cardio-endocrine
arker, in the situation of cardiac emergency, and further
nalyzed inﬂuence of renal function on these evaluations for
he prognostic implications.
atients and methods
atients
onsecutive 162 patients (age, 63.7± 1.1 years; 107 males
nd 55 females) who were admitted to the cardiac emer-
ency room of Nippon Medical School Hospital during
999—2000 because of chest pain or dyspnea were enrolled.
ll 162 patients underwent standard 12-lead electrocardiog-
aphy in the cardiac emergency room immediately after the
isit. The demographic data, history of hypertension, dys-
ipidemia, diabetes mellitus, and smoking were investigated
n admission. Echocardiography was performed within 24 h
f admission to assess left ventricular function.
xclusion criteria
atients on chronic hemodialysis because of chronic renal
ailure were excluded from the present study.ethods
lood sampling
fter informed consent was obtained, blood was collected
ith the patient in the supine position on admission by
F
T
i
gology. Published by Elsevier Ireland Ltd. All rights reserved.
irect venipuncture of an antecubital vein. Blood samples
ere collected into tubes containing EDTA and centrifuged
ithin 30min, after which plasma CK-MB was measured
y an immunoinhibition assay (NAC, Merck, Darmstadt,
ermany), H-FABP by two-step direct sandwich-ELISA quan-
itative measures (Market-M, Dainippon Pharmaceutical
o., Osaka, Japan), and TnT levels by an electrochemi-
uminescence assay (Elecsys 2010, Roche Diagnostics,
annheim, Germany). Simultaneously obtained plasma was
tored at −80 ◦C until analysis of NT-proBNP. Plasma
evels of NT-proBNP were measured by an electrochemi-
uminescence assay (Elecsys 2010). Estimated glomerular
ltration rate (eGFR) was calculated by the modiﬁcation
f diet in renal disease equation modiﬁed by a Japanese
oefﬁcient.
chocardiography
ransthoracic two-dimensional echocardiography was per-
ormed in all patients within 24 h of admission by an
xperienced cardiologist without the knowledge of cardiac
arkers data. The left ventricular end-diastolic diameter
nd end-systolic diameter were measured according to the
uidelines of the American Society of Echocardiography. The
eft ventricular ejection fraction (LVEF) was calculated by
he modiﬁed Simpson’s method.
iagnostic criteria
lectrocardiographic ﬁndings at presentation and ﬁnal diag-
oses at discharge were analyzed for all patients. The
iagnoses were classiﬁed into 6 groups: (1) acute coronary
yndrome (ACS); (2) unstable angina (UA) without TnT ele-
ation; (3) worsening congestive heart failure (CHF); (4)
rrhythmias; (5) other cardiopulmonary disease; and (6)
on-cardiopulmonary etiology. The ACS consisted of acute
yocardial infarction (AMI) and unstable angina with TnT
levation (>0.02 ng/ml). The diagnosis of AMI was made on
he basis of two or three of the following World Health Orga-
ization criteria: (1) prolonged chest pain; (2) development
f a new Q wave following ST elevation, or prolonged ST
epression, or T wave inversion; and (3) characteristic ele-
ation of serum CK (more than twice the upper limit) and
K-MB fraction (more than 10% of total CK or more than
wice the upper limit). UA was deﬁned according to Braun-
ald’s criteria, and UA with TnT elevation (>0.02 ng/ml) was
lassiﬁed as ACS. The diagnosis of CHF was made accord-ollow-up analysis
o evaluate the prognostic value of the cardiac markers
n early risk stratiﬁcation, in-hospital survival was investi-
ated.
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NN-terminal pro-BNP is a novel biomarker for integrated card
Statistical analysis
The cardiac markers and other continuous variables are
expressed as mean± standard error of mean (S.E.M.). Com-
parison of cardiac markers between the diagnosis groups
was assessed by Kruskal—Wallis test or Turkey—Kramer test.
Linear regression analysis was done, and correlation coef-
ﬁcients were calculated to assess the relations between
NT-proBNP levels and CK-MB, H-FABP, TnT, and LVEF, and
between eGFR and NT-proBNP, CK-MB, H-FABP, and TnT lev-
els. To investigate the prognostic value of cardiac markers
in the setting of cardiac emergency, in-hospital survival was
analyzed by Kaplan—Meier analysis. The predictive value of
8 variables (male, age, log NT-proBNP, H-FABP, CK-MB, TnT,
LVEF, and eGFR) was tested in a Cox proportional hazard
regression analysis. NT-proBNP levels were transformed to
the logarithm in a Cox proportional hazard regression anal-
ysis. p-Values less than 0.05 were considered statistically
signiﬁcant.
The present study protocol was in agreement with
the guideline of the institutional ethics committee, and
informed consent was obtained from all patients before
study entry.
Results
Patient demographics
Three patients on chronic hemodialysis because of chronic
renal failure were excluded from the present study. Baseline
characteristics of the studied patients are shown in Table 1.
The mean age was 63.7± 1.1 years, and 107 patients (66.0%)
were men. Of the 162 patients, 84 (51.9%) were hyperten-
sive, 51 (31.5%) were dyslipidemic, 37 (22.8%) had diabetes
mellitus, and 89 (54.9%) were smokers. The mean serum cre-
atinine level was 1.20± 0.62mg/ml, and mean eGFR was
58.3± 1.81ml/min.Final diagnosis and backgrounds
Final diagnosis, clinical backgrounds, and in-hospital mor-
tality are shown in Table 2. The arrhythmias group consisted
of 6 patients with paroxysmal atrial ﬁbrillation and 4
p
l
C
d
Table 1 Study population (n = 162).
Clinical features
Age, mean± S.E.M.
Male (%)
Coronary risk factor (%)a
Diabetes mellitus
Hypertension
Hyperlipidemia
Smoking
Ejection fraction, % (mean± S.E.M.)
Glomerular ﬁltration rate, ml/min (mean± S.E.M.)
Creatine, mg/ml (mean± S.E.M.)
Hemoglobin, g/dl (mean± S.E.M.)
a Details of previous history were assessed in 162 patients at visit ornal burden and early risk stratiﬁcation 379
atients with sustained ventricular tachycardia or com-
lete atrioventricular block. The other cardiopulmonary
iseases consisted of 4 patients with acute aortic dissec-
ion diagnosed by computed tomography and/or magnetic
esolution imaging, 2 patients with pleuritis, 2 patients
ith pulmonary thromboembolism diagnosed by ventilation-
erfusion lung scanning and/or pulmonary angiography,
nd 1 patient with pericarditis, 1 patient with rupture of
bdominal aortic aneurysm, and 2 patients with intersti-
ial pneumonia and 1 patient with pneumonia. There were
o signiﬁcant differences in age, gender, and prevalence
f risk factors between groups, however LVEF in the CHF
roup was signiﬁcantly lower compared with other groups
p < 0.0001).
orrelations between cardiac markers, LVEF, and
enal function
omparison of cardiac markers between groups is shown
n Table 3. Mean NT-proBNP level in CHF was signiﬁcantly
igher compared with other groups (p < 0.0001). Mean TnT
evels in ACS was signiﬁcantly higher than those in other
roups (p < 0.0001), and mean H-FABP in ACS was also sig-
iﬁcantly higher than those in other groups except for CHF
roup (p < 0.001).
Correlations between cardiac markers, eGFR, and LVEF in
ll patients (n = 162, Table 4A), and in the patients with ACS
n = 80, Table 4B) were analyzed. In the whole study popu-
ation, there were signiﬁcant correlations between H-FABP
nd TnT (r = 0.409, p < 0.001) and CK-MB (r = 0.254, p < 0.01),
nd between TnT and CK-MB (r = 0.512, p < 0.001). How-
ver, NT-proBNP did not show signiﬁcant correlations with
ther cardiac markers. NT-proBNP signiﬁcantly correlated
ith LVEF (r =−0.407, p < 0.001), and H-FABP also signif-
cantly correlated with LVEF (r =−0.253, p < 0.01). When
nalyzing the correlations of cardiac markers and renal func-
ion, there were signiﬁcant correlations between eGFR and
T-proBNP (r =−0.466, p < 0.001) and H-FABP (r =−0.235,
< 0.01).
In the patients with ACS, there were signiﬁcant corre-
ations between TnT and H-FABP (r = 0.352, p < 0.01) and
K-MB (r = 0.528, p < 0.001) (Table 4B), however NT-proBNP
id not show a signiﬁcant correlation with other cardiac
Value
63.7± 1.1 years
107/162 (66.0)
37/162 (22.8)
84/162 (51.9)
51/162 (31.5)
89/162(54.9)
55± 1.3
58.3± 1.81
1.20± 0.62
13.3± 0.2
after hospitalization.
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Table 2 Baseline characteristics of the study population.
ACS (80) UA (23) CHF (10) Arrhythmia (11) Other-CP (13) Non-cardiac (25)
Male (%) 55 (69) 17 (74) 7 (70) 7 (64) 11 (85) 10 (40)
Age, years 63± 1.3 66± 2.2 67± 5.0 66± 4.4 64± 4.4 59± 4.3
DM (%) 22 (28) 6 (26) 2 (20) 0 (0) 4 (31) 2 (8)
HT (%) 42 (53) 16 (70) 5 (50) 3 (27) 9 (69) 5 (20)
HL (%) 31 (39) 10 (43) 3 (30) 1 (9) 2 (15) 2 (8)
Smoking (%) 51 (64) 16 (70) 3 (30) 5 (45) 9 (69) 4 (16)
EF (%) 54.5± 1.6 61.8± 2.0 30.8± 4.4** 52.8± 7.1 57.5± 3.6 60.8± 2.7
eGFR (ml/min per 1.73m2) 59.7± 2.63 56.4± 4.24 33.1± 6.91 52.6± 7.35 61.6± 6.70 62.3± 5.05
Cre (mg/dl) 1.17± 0.08 1.20± 0.10 1.64± 0.19* 1.25± 0.17 1.1± 0.12 1.22± 0.22
ACS: acute coronary syndrome; UA: unstable angina; CHF: congestive heart failure; CP: cardiopulmonary disease; DM: diabetes mellitus;
HT: hypertension; HL: hyperlipidemia; EF: ejection fraction; eGFR: estimated glomerular ﬁltration rate; Cre: creatinine.
* p < 0.001
** p < 0.0001
Table 3 Comparison of cardiac markers.
N NT-proBNP (pg/ml) TnT (ng/ml) H-FABP (ng/ml)
ACS 80 3129 ± 772 2.20 ± 0.46** 103 ± 22.1*
UA 23 1336 ± 516 0.01 ± 0.002 10.0 ± 2.19
CHF 10 11,114 ± 4216** 0.15 ± 0.07 44.1 ± 14.0
Arrythmia 11 2764 ± 1524 0.05 ± 0.02 9.06 ± 1.57
Other Cardiopulmonary 13 3548 ± 1042 0.43 ± 0.41 16.8 ± 6.06
Non-cardiac 25 2751 ± 1474 0.01 ± 0.003 11.9 ± 3.88
Values are expressed as mean± S.E.M.
ACS: acute coronary syndrome; CHF: worsening congestive heart failure; H-FABP: heart-type fatty acid-binding protein; NT-proBNP:
N-terminal pro B-type natriuretic peptide; TnT: troponin T; UA: unstable angina.
* p < 0.001.
** p < 0.0001.
Table 4A Correlations between cardiac markers and eGFR in the total patient population (n = 162).
NT-proBNP H-FABP TnT CK-MB EF
NT-proBNP 0.207 0.060 0.145 −0.407**
H-FABP 0.409** 0.254* −0.253*
TnT 0.512** −0.172
CK-MB −0.188
eGFR −0.466** −0.235* −0.166 −0.076 0.334*
CK-MB: creatinine kinase MB fraction; EF: ejection fraction; eGFR: estimated glomerular ﬁltration rate; H-FABP: heart-type fatty acid-
binding protein; NT-proBNP: N-terminal pro B-type natriuretic peptide; TnT: troponin T.
* p < 0.01.
** p < 0.001.
Table 4B Correlations between cardiac markers and eGFR in patients with ACS (n = 80).
NT-proBNP H-FABP TnT CK-MB EF
NT-proBNP 0.042 0.101 0.130 −0.228
H-FABP 0.352* 0.226 −0.336*
TnT 0.528** −0.230
CK-MB −0.177
GFR −0.552** −0.272 −0.203 −0.038 0.223
CK-MB: creatinine kinase MB fraction; EF: ejection fraction; eGFR: estimated glomerular ﬁltration rate; H-FABP: heart-type fatty acid-
binding protein; NT-proBNP: N-terminal pro B-type natriuretic peptide; TnT: troponin T.
* p < 0.01.
** p < 0.001.
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Table 5 Multivariate analyses assessment for subsequent cardiac death.
Univariate analysis Multivariate analysis
Coefﬁcient 95%CI p-Value Coefﬁcient 95%CI p-Value
Male 1.606 0.420—6.136 0.488
Age 1.036 0.976—1.100 0.241
H-FABP 1.003 1.002—1.005 <0.001 1.001 0.998—1.003 0.656
TnT 1.119 0.965—1.297 0.138
CK-MB 1.000 0.987—1.013 0.975
log NT-proBNP 1.000 1.000—1.000 <0.001 1.000 1.000—1.000 0.008
EF 0.903 0.847—0.964 0.002 0.879 0.783—0.986 0.027
eGFR 0.962 0.935—0.990 0.0
CK-MB: creatinine kinase MB fraction; EF: ejection fraction; eGFR: est
binding protein; NT-proBNP: N-terminal pro B-type natriuretic peptide
markers. There was a signiﬁcant and close correlation
between eGFR and NT-proBNP (r =−0.552, p < 0.001). In
ACS group, only H-FABP signiﬁcantly correlated with LVEF
(r =−0.336, p < 0.01) and other markers did not show a sig-
niﬁcant correlation.
Prognostic value of cardiac markers
During the hospitalization, 9 patients died. In-hospital mor-
tality was 4.9% for ACS, 0% for UA, 36.4% for CHF, 0%
for arrhythmias, 3.9% for other cardiopulmonary, and 0%
for non-cardiopulmonary groups. The results of multivari-
ate analyses assessment among 8 variables for subsequent
cardiac death are shown in Table 5. As a result of uni-
variate analysis, H-FABP, log NT-proBNP, LVEF, and eGFR
provided prognostic information, but as a result of multivari-
ate analysis, only log NT-proBNP and LVEF were independent
prognostic predictors.
Kaplan—Meier survival curves in patients with NT-proBNP
levels above and below the median level of 689 pg/ml are
shown in Fig. 1. The cumulative event-free rate during the
hospitalization was signiﬁcantly higher in patients with NT-
proBNP <689 pg/ml compared with those with NT-proBNP
>689 ng/ml (p < 0.0001).
Figure 1 Kaplan—Meier survival curves in patients with N-
terminal pro-B-type natriuretic peptide (NT-proBNP) levels
above and below the median level of 689 pg/ml. The cumula-
tive event-free rate during the hospitalization was signiﬁcantly
higher in patients with NT-proBNP <689 pg/ml compared with
those with NT-proBNP >689 ng/ml (p < 0.0001).
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imated glomerular ﬁltration rate; H-FABP: heart-type fatty acid-
; TnT: troponin T.
iscussion
NP is a cardiac neurohormone predominantly secreted by
he ventricles in response to increased myocardial stretch,
all tension, or other myocardial stress [13—16]. ProBNP
s synthesized as a pro-hormone by cardiac myocytes, and
ndergoes enzymatic cleavage to produce BNP and NT-
roBNP. Serum level of NT-proBNP is elevated in patients
ith left ventricular dysfunction and shows a close correla-
ion with the BNP level [17—19]. We have reported that the
bsolute increment of NT-proBNP exceeds that of BNP, and
T-proBNP would be a more discerning marker for the detec-
ion and evaluation of cardiac dysfunction compared with
NP [7]. Furthermore, large-scale clinical trials have shown
hat NT-proBNP is elevated in patients with ACS, and con-
ributed as a powerful predictor of both short and long-term
ortality [20—23].
ifferences in NT-proBNP elevation in the
tiologies
n the present study, we classiﬁed the patients into 6
tiologies: ACS (AMI and UA with TnT elevation); UA
without TnT elevation); CHF; arrhythmias; other car-
iopulmonary diseases; and non-cardiopulmonary diseases.
T-proBNP levels were elevated remarkably in all groups
ompared with the upper limit for the control (mean + 2S.D.:
3.7 + 30.88 pg/ml, 54.5 pg/ml) from our previous data [7].
he elevation was especially notable in patients with wors-
ning CHF as previously well documented, which would
eﬂect sustained elevation of left ventricular end-diastolic
all stress and reduced LVEF [24]. The elevation of NT-
roBNP in patients with ACS and UA may relate to increased
eft ventricular wall stretch resulting from left ventricular
egmental asynergy following myocardial ischemia. Myocar-
ial ischemia per se may be another mechanism leading to
levation of NT-proBNP besides the ischemia-induced left
entricular segmental asynergy and wall stress. We have
ecently reported that NT-proBNP was elevated signiﬁcantly
igher in non-ST-elevation ACS patients rather than those
ith ST-elevation ACS patients especially in the early phase
f the onset [9]. Comparison of NT-proBNP and TnT levels
n ACS patients revealed marked differences; signiﬁcantly
ugmented elevation of NT-proBNP in non-ST-elevation ACS
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roup as compared with prominent elevation of TnT in ST-
levation ACS group, suggesting a larger ischemic insult
eveloping in non-ST-elevation ACS despite the smaller
xtent of myocardial necrosis. The other cardiopulmonary
roup also showed elevated levels of NT-proBNP, which may
eﬂect abrupt elevation of myocardial wall stress associated
ith the development of acute aortic dissection or acute
ulmonary thromboembolism. Arterial hypoxia accompa-
ied with these disorders may also relate to the elevation of
T-proBNP. In the case of shock developing from acute aortic
issection or pulmonary thromboembolism, abrupt decrease
n renal blood ﬂow and renal function may also relate to
arked elevation of NT-proBNP, since renal excretion is
egarded as its main clearance mechanism [25]. More recent
ata suggest that NT-proBNP concentrations in patients with
hronic kidney disease or renal insufﬁciency may parallel the
resence and severity of cardiac abnormalities and offer
owerful prognostic information in such patients as well
26,27]. Thus, elevation of NT-proBNP is not necessarily dis-
ase speciﬁc, rather reﬂecting hemodynamic deterioration,
yocardial wall stress, myocardial ischemia, derangements
n volume loading conditions, and renal function.
orrelation between NT-proBNP and other cardiac
arkers in ACS
nalyses of correlations between NT-proBNP and other
ytosolic or myoﬁbril markers revealed that NT-proBNP did
ot necessarily show signiﬁcant correlations with these
arkers in the ACS group despite there being signiﬁcant
orrelations between TnT and H-FABP and CK-MB. Actu-
lly, NT-proBNP signiﬁcantly correlated with LVEF in the ACS
roup in the present study. These data demonstrated that
T-proBNP is different from the conventional myocardial
amage markers, and is to be a cardiac stress marker. Fur-
hermore, it should be noted that there was a signiﬁcant and
lose correlation between NT-proBNP and eGFR.
arker of integrated cardio-renal insults
e previously reported the prognostic signiﬁcance of cardio-
enal subset in patients with acute myocardial infarction,
hich was classiﬁed by initial stroke volume (above or below
8ml/beat/m2) and serum creatinine levels (above or below
.5mg/dl) [28]. The cardio-renal subset clearly discrimi-
ated 6-month survival, and patients with stroke volume
ndex <28ml/beat/m2 and serum creatinine >1.5mg/dl
howed 100% mortality as compared with 4.3% in those
ith stroke volume index >28ml/beat/m2 and creatinine
1.5mg/ml (odds ratio: 23.3). In the situation of CHF, Hel-
iage et al. clariﬁed that renal function is the most powerful
redictor of the prognosis rather than New York Heart Asso-
iation class, LVEF, or the use of angiotensin-converting
nzyme inhibitor [29]. In the GUSTO IV (Global Utilization
f Strategies To Open occluded arteries IV) substudy, NT-
roBNP was found to be related to short-term and long-term
ortality, and NT-proBNP in combination with creatinine
learance provided the best prediction of mortality for
atients with ACS [30]. Thus it should be clear that renal
unction per se or NT-proBNP, as a reﬂection of the inte-
rated cardio-renal burden is the most important prognosticT. Yamashita et al.
redictor in patients with acute or chronic heart failure
s well as those with ACS. Luchner et al. positioned the
ole of NT-proBNP as the integrated cardio-renal marker,
ince it closely correlated with both LVEF and renal func-
ion in their study of patients with AMI [31]. A recent
eport by Kimmenade et al. revealed that the combination
f NT-proBNP and eGFR better predicts short- and long-term
utcome in acute heart failure than either parameter alone.
hey showed that patients with NT-proBNP level above
he median (4647 pg/ml) and an eGFR <60ml/min/1.73m2
howed most poor prognosis compared with other categories
ncluding patients with an eGFR <60ml/min/1.73m2 but
ith NT-proBNP below the median. Thus NT-proBNP seems
ore useful to delineate the cardio-renal insults than the
onventional assessments [32]. The present study conﬁrmed
hat NT-proBNP signiﬁcantly correlated with eGFR rather
han LVEF, and NT-proBNP is the most powerful prognostic
redictor in the situation of cardiac emergency in terms
f the integrated cardio-renal marker for the patients with
CS, acute heart failure, arrhythmias, and other diseases.
tudy limitations
n the present study, initial values of cardiac markers on
dmission were analyzed. A recent study revealed more
han 20% of the patients admitted because of heart failure
r ACS presented worsening renal function within a week
fter hospitalization which plays a crucial role contributing
o the outcome. Thus dynamic changes in serum creatinine
nd other cardiac markers in the setting of cardiac emer-
ency should be analyzed in a larger number of subjects. The
resent ﬁndings would lend support to the establishment of
herapeutic strategies aimed to suppress the cardio-renal
urden to improve the prognosis in these patients.
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